Ondansetron Zydus

Ondansetron, the active ingredient in Ondansetron Zydus, is a 5-HT3 receptor antagonist presented as an oral tablet for oral use. It is employed to prevent and treat nausea and vomiting associated with chemotherapy, radiotherapy and surgery. GNH USA supplies Ondansetron Zydus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ondansetron acts on the serotonergic pathway to control nausea and vomiting in several clinical settings. - Chemotherapy‑induced nausea and vomiting: prevents and treats nausea and vomiting caused by cytotoxic chemotherapy. - Radiation‑induced nausea and vomiting: reduces nausea and vomiting that occur after radiotherapy. - Postoperative nausea and vomiting: helps control nausea and vomiting following surgical procedures.

Common Side Effects: - Headache: mild to moderate headache may occur. - Constipation: reduced bowel movements are frequently reported. - Dizziness: patients may feel light‑headed or unsteady. - Fatigue: a feeling of tiredness can be experienced. - Diarrhoea: loose stools may develop. - Abdominal pain: discomfort in the stomach area is possible.

Serious or Rare Side Effects: - QT prolongation: may cause abnormal heart rhythm. - Severe allergic reaction: includes rash, swelling, or anaphylaxis. - Serotonin syndrome: rare but serious condition when combined with other serotonergic drugs. - Cardiac arrhythmia: irregular heartbeat in susceptible individuals. - Stevens‑Johnson syndrome: rare severe skin reaction.

Before initiating therapy, consider the following precautions. - Assess cardiac risk: evaluate QT interval and electrolyte status. - Review medication history: identify other QT‑prolonging agents. - Monitor for hypersensitivity: watch for signs of allergic reaction. - Use with caution in hepatic impairment: dose adjustment may be required. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Ondansetron may interact with several drug classes. Major Interactions (Avoid): - Apomorphine: can cause severe hypotension and loss of consciousness. - Other QT‑prolonging drugs: increase risk of cardiac arrhythmias. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): may precipitate serotonin syndrome. Moderate Interactions (Monitor Closely): - Dexamethasone: may enhance antiemetic effect, monitor for additive side effects. - Carboplatin: may increase risk of QT prolongation. - Anesthetic agents: may require dose adjustments during surgery.